ArticleCureus2026
Recurrent Radiation-Induced Angiosarcoma of the Breast Without Distant Metastasis: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiation-induced sarcomas represent a rare but aggressive complication following breast cancer treatment, often associated with significant biological heterogeneity and limited therapeutic options. Their clinical course is frequently characterized by high recurrence rates and limited responsiveness to conventional therapies. We report a case of a 76-year-old female with a history of left-sided breast cancer treated in 2017, who subsequently developed a high-grade radiation-induced soft tissue sarcoma of the chest wall. The patient underwent multiple surgical resections due to recurrent disease. Systemic treatment included exemestane as endocrine therapy and pazopanib as antiangiogenic targeted therapy, both administered according to a consistent daily schedule. Laboratory findings demonstrated a relatively stable neutrophil-to-lymphocyte ratio of approximately 3.0-3.5 in the context of a persistent inflammatory profile. Despite aggressive tumor biology and multiple comorbidities, the patient maintained a relatively stable clinical condition without evidence of distant metastasis. An additional observation in this case was the consistent daily timing of systemic therapy administration. While not formally evaluated, this pattern may represent a potentially relevant aspect of treatment delivery and could warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.